Tissue Engineered Skin Substitutes - (0068) — MM 0068 | CIGNA Coverage Update

Cigna modified MM 0068 covering tissue engineered skin substitutes, effective January 16, 2026. Here's what changes for billing teams.

Cigna Healthcare updated its tissue engineered skin substitutes coverage policy under MM 0068, affecting 52 CPT codes and 137 HCPCS codes tied to skin graft procedures, wound healing, and biologic implants. The update draws a sharper line between what's medically necessary and what's experimental — and with reimbursement at stake across codes like CPT 15271–15278 (skin substitute graft applications) and dozens of Q-series HCPCS products, billing teams need to know exactly which side of that line their claims fall on.

Quick-Reference: Cigna MM 0068 Tissue Engineered Skin Substitutes (2026)

Cigna Tissue Engineered Skin Substitutes Coverage Criteria and Medical Necessity Requirements 2026

The Cigna tissue engineered skin substitutes coverage policy under MM 0068 splits the code set into two buckets: procedures considered medically necessary when criteria are met, and procedures considered experimental, investigational, or unproven (EIU).

The medically necessary bucket includes standard autograft procedures — split-thickness, full-thickness, epidermal, and dermal autografts — along with tissue cultured skin autografts and skin substitute graft applications. CPT codes 15100, 15101, 15110, 15111, 15120, 15121, 15130, 15131, 15135, and 15136 (autograft procedures for trunk, arms, legs, face, and genitalia) fall here, as do the skin substitute graft application codes CPT 15271 through 15278. The phrase "when criteria in the applicable section are met" is doing a lot of work in this policy. Medical necessity isn't automatic — documentation must support the specific indication.

The EIU bucket is where claims get denied. Skin cell suspension autograft codes (CPT 15011–15018) are all flagged experimental. So are several nerve repair codes — CPT 64910, 64912, 64913, and 64999 — along with CPT 15778 for absorbable mesh implantation and CPT 46707 for anorectal fistula repair with plug. If your practice bills any of these, a claim denial is the expected outcome under this policy.

Prior authorization requirements aren't explicitly enumerated in the policy summary, but with a policy this large and a payer as audit-active as Cigna, assume prior auth is required for any biologic skin substitute product before the procedure date. Verify prior authorization requirements with Cigna directly for each product code. The reimbursement exposure on a single skin substitute application can run into thousands of dollars — prior auth confirmation protects that revenue.

Cigna Skin Substitute Exclusions and Non-Covered Indications

The experimental/investigational/unproven designations in this policy are the real claims risk. Cigna explicitly excludes a significant number of products and procedures.

On the CPT side, all eight skin cell suspension autograft codes (15011 through 15018) are EIU. These cover everything from harvest and enzymatic processing to application — the entire workflow for this product type is non-covered. If your burn program or wound care center has been building charges around ReCell or similar suspension autograft products, Cigna won't pay.

The nerve repair codes flagged EIU — CPT 64910 (synthetic conduit or vein allograft), 64912 and 64913 (nerve allograft, first and additional strands), and 64999 (unlisted nervous system procedure) — are a quiet revenue risk for practices that bundle these with reconstructive wound care. These aren't wound care codes on their face, but they show up in this policy because of the biologic scaffold overlap.

On the HCPCS side, the EIU list is extensive. Products billed under codes like A2004 (Xcellistem), A2005 (Microlyte Matrix), A2020 (AC5 Advanced Wound System), A2021 (Neomatrix), A2033 (Myriad Morcells), A2039 (Innovamatrix FD), Q4103 (Oasis Burn Matrix), Q4113 (GraftJacket Xpress), Q4114 (Integra Flowable Wound Matrix), Q4118 (Matristem Micromatrix), Q4125 (Arthroflex), Q4126 (Memoderm/Dermaspan/Tranzgraft/Integuply), Q4130 (Strattice TM), Q4137 (Amnioexcel/Amnioexcel Plus/Biodexcel), and Q4138 (Biodfense Dryflex) are all EIU. This is not a short list. If your wound care or surgical team selects products from a formulary, that formulary needs to be cross-checked against this policy before January 16, 2026.

Connective tissue (C1762), vascular grafts (C1768), and several collagen-based nerve protector products — C9352 (NeuraGen Nerve Guide), C9353 (NeuraWrap Nerve Protector), C9355 (NeuroMatrix), C9356 (TenoGlide Tendon Protector), C9361 (NeuroMend Collagen Nerve Wrap) — are also EIU. So are the bovine collagen dermal substitutes C9358 and C9360 (SurgiMend) and C9364 (Permacol). Add A6010 (collagen-based wound filler), C9354 (Veritas pericardial matrix), and J3590 (unclassified biologics) to the denial list.

The real issue here: a lot of these EIU products are widely used in wound care and reconstructive surgery. Cigna saying they're experimental doesn't mean clinicians stop using them. It means your claims will be denied, and your accounts receivable will grow.

Coverage Indications at a Glance

Cigna Tissue Engineered Skin Substitutes Billing Guidelines and Action Items 2026

CPT, HCPCS, and ICD-10 Codes for Tissue Engineered Skin Substitutes Under MM 0068

Covered CPT Codes (When Medical Necessity Criteria Are Met)

Not Covered / Experimental CPT Codes

Not Covered / Experimental HCPCS Codes

The full policy lists 137 HCPCS codes total. The codes shown above represent the codes explicitly provided in the source data. Access the complete MM 0068 code set at app.payerpolicy.org.